Loading clinical trials...
Loading clinical trials...
A Prospective Observational Study to Evaluate Quality of Life and Costs in a Real Life Setting in Patients Treated With 90Y-Zevalin
Conditions
Interventions
[90]Y-ibritumomab tiuxetan (Zevalin, BAY86-5128)
Locations
1
Belgium
Many Locations, Belgium
Start Date
August 1, 2007
Primary Completion Date
May 1, 2009
Completion Date
May 1, 2009
Last Updated
August 24, 2010
NCT06189391
NCT05006716
NCT06026319
NCT05950165
NCT06876662
NCT05755087
Lead Sponsor
Bayer
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions